Roots Analysis

FEBRUARY 26, 2024

Several Technology Providers, with Proprietary Platforms, have Emerged as Key Enablers Several technology developers have licensed their platforms to other pharmaceutical companies for developing subcutaneous formulation of their approved / pipeline products.

Drug Delivery Systems 52

Drug Delivery Systems Drug Delivery Drugs Contract Manufacturing 52

pharmaphorum

MARCH 14, 2022

This morning, Sandoz announced it has acquired medical and drug delivery device specialist Coalesce Product Development, bolstering its capabilities for the development of respiratory medicines and ‘complex’ generics. The post Sandoz bulks up ahead of possible sale with Coalesce buy appeared first on.

Sales 89

Sales Drug Delivery Marketing Production 89

Delveinsight

MARCH 2, 2021

To sum it, Chinook will manage clinical development and commercialization of product candidates while Evotec will be eligible for an undisclosed upfront payment, research funding, progress-dependent milestone payments, and tiered royalties on net sales for targets identified through the collaboration.

Drug Delivery 40

Drug Delivery Research Drugs Gene Editing 40

Drug Discovery World

APRIL 29, 2024

Dr Andrew Lewis, Chief Scientific Officer; Kieron Hall, Chief Marketing Officer; and Eric Bironneau, Chief Business Officer, Quotient Sciences: Lewis has held various scientific leadership positions at Quotient and was previously Director of Novel Drug Delivery Technologies at Ipsen.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

pharmaphorum

MARCH 15, 2022

In return, it will get a royalty on sales if the new version gets approved. It’s an example of a fairly uncommon risk-sharing model, in which an investment group funds a clinical development programme in the hope of a bigger payoff down the line, with rights to the drug staying with the pharma partner.

Trials 86

Trials Sales Drug Delivery Antibody 86

pharmaphorum

OCTOBER 18, 2021

•Engage in the growing advances and development of RNA tools for vaccines and anti-infectives. Chair for 2022: Heinrich Haas, VP RNA Formulation and Drug Delivery, BioNTech. Who should attend: •Research & Development Directors/Managers/Scientists. Heads of Clinical Development. Hashtag: #SMiRNA.

RNA 52

RNA Drug Delivery Scientist Clinical Development 52

The Pharma Data

JANUARY 3, 2021

The Company’s pipeline leverages its proprietary bioerodible Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential six-month sustained delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration.

Production 52

Production Sales Development Licensing 52